The pursuit of eradicating HIV has seen some transformative innovations.
In June, the FDA greenlit Yeztugo (Renacapavir), a revolutionary HIV prevention treatment requiring just two injections annually. Remarkably, it achieved a 99% success rate in trials. This significant advancement could change the game for individuals who struggle to maintain daily oral prevention methods, offering a more manageable alternative.
However, this exciting progress may be overshadowed by the Trump administration’s proposal to cut nearly $1 billion from the Federal HIV Prevention Program. While treatments like Renacapavir could be vital in combating the epidemic, they need adequate resources and policies to ensure they reach those who need them most.
Despite Renacapavir’s impressive effectiveness, access is still a major concern. The annual cost is approximately $28,000, which poses a substantial barrier for the very communities that require it. We are awaiting details on programs from Gilead Sciences, the drug’s developer, and how the insurance market will respond. It’s not just about the drug price; there are also additional costs for lab work, provider visits, and follow-ups, which could complicate access to care.
It’s crucial that federal leadership takes action to ensure this new HIV prevention method effectively reaches those most in need. This means updating clinical guidelines, funding support services, and enhancing infrastructure for access.
Unfortunately, the current administration and the Republican majority in Congress are jeopardizing access to critical innovations. Their approach could dismantle the HIV budget of the CDC, undermining public health systems and hindering progress. The Republican budget deal signed by President Trump over the July 4th weekend proposes deep cuts to Medicaid, which is the primary funding source for HIV care in the U.S. Without strong federal support, expanding access to these new prevention tools becomes highly uncertain.
Even with the significant progress made in HIV prevention, many individuals in the LGBTQ+ community, especially black Southerners and those living in poverty in rural areas, still find that not all strategies effectively serve them. Our lived experiences demand options that truly reflect who we are and our realities.
Renacapavir truly offers substantial hope, but let’s be realistic. Science alone isn’t a panacea. The difference lies in equitable and intentional policies focused on our communities and public health frameworks that don’t leave anyone behind.
While there has been progress, it’s essential to acknowledge that black Americans account for 43% of all new HIV diagnoses in the U.S., despite representing only 13% of the population. The situation is even more dire for black transgender women, with a staggering 44% living with HIV, and their lifetime risk remains alarmingly high.
It’s also critical to consider geographic disparities. The South accounts for 52% of new HIV diagnoses, indicating a systemic failure. Barriers such as limited healthcare access, ongoing stigma, and inadequate sex education perpetuate this crisis. These obstacles prevent not only care but also the implementation of preventative measures.
For gay and bisexual black men, the lifetime risk of contracting HIV is around 50%. Tools like pre-exposure prophylaxis and Renacapavir are promising, but they only matter if individuals can access them without fear or shame. Ending the epidemic requires fostering an environment where people feel safe making informed health choices.
The fight against HIV isn’t solely a laboratory issue; it’s about how we can turn innovations into reality within our communities. Science plays its part, and it’s vital we advocate for Congress to maintain funding for CDC HIV prevention programs and fully support the HIV response. There are effective tools available, but dismantling support systems that communities rely on puts lives at risk.
The potential of Renacapavir—and the hope it embodies—should not be lost due to policy neglect. The question remains: will we ensure this breakthrough benefits everyone? Science has equipped us with the tools; now we must ensure everyone has the chance to utilize them.
